Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR⁺/HER2^-advanced breast cancer.

ABSTRACT:

Purpose

This study aims to evaluate the cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib-fulvestrant for treating advanced HR⁺/HER2^-breast cancer patients with PIK3CA mutations from both United States (U.S.) and Chinese healthcare system perspectives.

Methods

A partitioned survival model was used, with survival data from the INAVO120 clinical trials. Primary outcomes assessed were costs, life-years, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER). Sensitivity analysis was performed to explore the uncertainty of model inputs. Changes in treatment efficacy were modeled to assess their impact on cost-effectiveness. Subgroup analysis was also conducted to refine the findings.

Result

SUBMITTER: Zhu J 

PROVIDER: S-EPMC12809096 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature